ArriVent BioPharma, Inc. (AVBP) Stock Score, Valuation & Financial Research

ArriVent BioPharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for AVBP

ArriVent BioPharma, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 15.09. These figures are a research snapshot, not a buy or sell recommendation.

What ArriVent BioPharma, Inc. does

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

ArriVent BioPharma is a clinical-stage biopharmaceutical company that identifies, licenses, and globalizes biopharmaceutical innovations. Its business model relies on acquiring rights to product candidates from third-party developers and advancing them through clinical development and regulatory approval to generate future commercial revenue.

Products and services

  • The company is a clinical-stage entity focused on developing a pipeline of product candidates, including furmonertinib, which is currently in clinical trials for various oncology indications.

Customer types

Healthcare providers and patients (upon potential future commercialization).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party CROs to conduct and manage its clinical trials; specific supplier names are not disclosed. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party CMOs for the manufacturing of its product candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Allist Pharmaceuticals, Inc. — A strategic collaboration and license agreement for the development and commercialization of furmonertinib. Source
  • Lepu Biopharma Co., Ltd. — An exclusive license agreement entered into on January 21, 2025, for the development and commercialization of product candidates. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various established and emerging biopharmaceutical companies developing oncology therapies. Source

Business strengths to evaluate

  • Experienced management team with expertise in global drug development Source
  • Strategic licensing model to access global innovations Source

Business risks and research considerations

  • Dependence on third-party collaborators and licensors Source
  • Clinical trial failure and regulatory approval uncertainty Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

AVBP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 15.09
Market capitalization:
702.82M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -163.74M
Free cash flow:
USD -160.59M
Cash:
USD 154.68M
Total debt:
USD 351K
EPS:
USD -3.68

What stands out

  • Free cash flow is USD -160.59M, negative for the stored period.
  • The balance sheet shows USD 154.68M of cash versus USD 351K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 154.33M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for AVBP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can AVBP fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is AVBP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for AVBP to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of AVBP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research AVBP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.